Clinical trials: Glioblastoma Multiforme of Brain
Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
This phase I trial is studying the side effects and best dose of RO4929097 in treating patients with recurrent invasive gliomas. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
- Conditions
- Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01269411
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Metastatic Cancer
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in treating patients…
- Trial name
- NCT00009854
- Testing
- carmustine in ethanol, conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Direct Therapeutics
Glioblastoma, Glioblastoma (GBM)
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when administered twice into the brain where the tumor is located. This is a Phase IB 2 dosing study.
- Conditions
- Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III
- Trial name
- NCT06614855
- Testing
- C134
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- James Markert, MD
Brain Tumor, Recurring Glioblastoma
Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma
In the Netherlands a 2 center investigator-driven phase I/II clinical trial is initiated in June 2010 testing the oncolytic adenovirus Delta24-RGD to treat glioblastoma patients.
- Trial name
- NCT01582516
- Testing
- delta-24-RGD adenovirus
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System
S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00017147
- Testing
- carmustine, radiation therapy, O6-Benzylguanine
- Where
- 163 sites in United States
- Volunteers
- 183 people
- Sponsor
- SWOG Cancer Research Network
Astrocytoma, Glioblastoma
Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
Glioblastomas, the most frequent malignant brain tumor in adults, are widespread in the brain, despite their discrete appearance on computed tomography (CT) or magnetic resonance imaging (MRI).
- Conditions
- Astrocytoma, Glioblastoma, Glioma
- Trial name
- NCT00001148
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type)
Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.
Glioblastoma (GBM) is an aggressive cancer with a progression-free survival (PFS) of 7 months and an overall survival (OS) of 15 months. Many therapeutic approaches have failed to improve the prognosis of patients to date.
- Conditions
- Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type), Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide
- Trial name
- SonoFIRST (NCT04614493)
- Testing
- SonoCloud-9 (SC9) device, Temozolomide according Stupp protocol
- Where
- 7 sites in Belgium, France and 1 more
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Tumor, Glioma, Malignant
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo.
- Conditions
- Brain Tumor, Glioma, Malignant, Ependymoma, Oligodendroglioma
- Trial name
- PEAR-GLIO (NCT06038760)
- Testing
- Resection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Ourotech, Inc.
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
3T MRI Biomarkers of Glioma Treatment Response
This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01996527
- Testing
- 3-Tesla magnetic resonance imaging, CEST-MRI, DW-MRI
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Glioblastoma, Astrocytoma, Grade IV
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies.
- Trial name
- CerebralEDV (NCT02766699)
- Testing
- EGFR(V)-EDV-Dox
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Engeneic Pty Limited
Recurrent Glioblastoma, Glioblastoma Multiforme
Sonodynamic Therapy in Patients With Recurrent GBM
Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided…
- Conditions
- Recurrent Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- GBM 001 (NCT06039709)
- Testing
- 5-ALA and Low-Intensity Focused Ultrasound (SDT)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shayan Moosa, MD
Glioblastoma, Glioblastoma Multiforme
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
This phase I trial investigates the efficacy and safety of brain-targeting epidermal growth factor receptor chimeric antigen receptor immune cells (EGFRvIII-CAR T cells) in treating patients with leptomeningeal disease from…
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant
- Trial name
- CARTREMENDOUS (NCT05063682)
- Testing
- EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes
- Where
- 3 sites in Finland, India
- Volunteers
- 10 people
- Sponsor
- Chembrain LTD
Gliosarcoma, Glioblastoma
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
Primary Objective: To determine maximum tolerated dose \& dose limiting toxicity of vandetanib when combined with standard dosing of etoposide among patients with recurrent malignant glioma who are on \& not on enzyme-inducing…
- Trial name
- NCT00613223
- Testing
- Vandetanib and Etoposide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Annick Desjardins
Glioblastoma, Glioma of Brain
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.
- Trial name
- NCT03460782
- Testing
- Ipilimumab
- Where
- 11 sites in Albania, Bosnia and Herzegovina and 6 more
- Sponsor
- Center Trials & Treatment
Glioblastoma, Brain Tumor
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
The purpose of this study is to evaluate whether treating glioblastoma patients with sitagliptin can improve immune response against the tumor by targeting specific immune cells called myeloid-derived suppressor cells (MDSCs)…
- Trial name
- NCT07003542
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme
RATIONALE: Giving boron phenylalanine in different ways and measuring it in tissue in patients with glioblastoma multiforme may help in planning better radiation therapy, such as boron neutron capture therapy, for patients in the…
- Trial name
- NCT01233492
- Testing
- boron phenylalanine, mannitol, biologic sample preservation procedure
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Cancer Research UK
Brain and Central Nervous System Tumors
Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma
RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells.
- Trial name
- NCT00003751
- Testing
- penicillamine, radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
This study will combine the chemotherapy agent temozolomide with the investigational drug SCH66336 (an agent which interferes with new cell growth).
- Trial name
- NCT00038493
- Testing
- Temozolomide and SCH66336
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Brain Cancer
Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients
Glioblastoma is the most common and the most aggressive primary brain cancer in adults. Indeed, despite very intensive treatments (i.e.
- Trial name
- ONCOVIRAC (NCT03294486)
- Testing
- Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain and Central Nervous System Tumors
High Light and Low Light Dose PDT in Glioma
RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00118222
- Testing
- porfimer sodium, adjuvant therapy, conventional surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center